Whistleblower Investigation Delayed Approval Of Forest's Savella
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA missed the user fee goal date for Forest's Savella (milnacipran) due to an investigation of late-breaking whistleblower allegations, review documents for the fibromyalgia therapy show